Medicus Pharma Ltd. has completed enrollment of 90 patients in its Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of the Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of nodular basal cell carcinoma $(BCC)$ of the skin in the United States. The topline results of this trial are expected to be released before the end of the first quarter of 2026, with an End-of-Phase 2 (EOP2) meeting with the FDA planned for the first half of 2026. The study is being conducted at nine clinical sites in the US. Additionally, Medicus Pharma has initiated a separate study (SKNJCT-004) in the United Arab Emirates and has received regulatory and ethical approvals to expand the Phase 2 study to the United Kingdom. No final results have been presented yet; they are expected in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601942-en) on December 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.